KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Debt: 2017-2024

Historic Total Debt for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $2.4 billion.

  • Amneal Pharmaceuticals' Total Debt rose 7.49% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 7.49%. This contributed to the annual value of $2.4 billion for FY2024, which is 6.98% down from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Total Debt is $2.4 billion, which was down 6.98% from $2.6 billion recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Debt peaked at $2.8 billion during FY2020, and registered a low of $2.4 billion during FY2024.
  • Its 3-year average for Total Debt is $2.5 billion, with a median of $2.6 billion in 2023.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Total Debt rose by 5.66% in 2020 and then decreased by 6.98% in 2024.
  • Amneal Pharmaceuticals' Total Debt (Yearly) stood at $2.8 billion in 2020, then declined by 1.86% to $2.7 billion in 2021, then fell by 2.78% to $2.7 billion in 2022, then decreased by 3.28% to $2.6 billion in 2023, then decreased by 6.98% to $2.4 billion in 2024.